Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Abiraterone Acetate Tablets (250mg)
ELC GROUP S.r.o. Czech Republic flag Czech Republic
Abstract ID:
Abiraterone Acetate is the generic form of branded drug ZYTIGA® used along with prednisone to treat men with castration-resistant prostate cancer (cancer that is resistant to medical or surgical treatments) that has spread to other parts of the body....
Contact Rishi Jacob
Participants
You
Email me a copy of this message

Abiraterone acetate is indicated for use in combination with prednisone as a treatment for metastatic castration-resistant prostate cancer. It has received FDA approval on 28 April 2011, EMA approval on 23 September 2011, MHRA approval on 5 September 2011 and TGA approval on 1 March 2012 for this indication. Zytiga has been one of Johnson & Johnson’s best new drug launches with global sales totalling $2.2 billion in 2015.

Type of Business Relationship Sought
Out Licensing
FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development CLINICAL TRIALS
CORPORATION